Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
L-701324 (L701324), a novel, potent and selective NMDA/glycine receptor antagonist, is an orally bioactive and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor. L-701324 exhibits a beneficial action in the animal model of parkinsonian rigidity. Pre-treatment with L-701,324 improves pharmacosensitivity in a mouse kindling model.
ln Vivo |
In the forced swim test (FST) and tail suspension test (TST), L-701324 (5–10 mg/kg; i.p.; once) shows antidepressant-like potential without influencing mice's locomotor activity [1]. In the chronic unpredictable mild stress (CUMS) depression model, L-701324 (5-10 mg/kg; i.p.; daily for 2 weeks) shows strong antidepressant-like effects, inhibits CUMS-induced europagenesis, and decreases BDNF signaling cascades in the hippocampus [1]. L-701324 (2.5–5 mg/kg; oral; once) decreases unconditioned and unconditioned anxiety-like behaviors while inhibiting NMDA receptor activity by blocking the NMDA/glycine-sensitive region on the NMDA receptor. circumstances including conditional conflict behavior[2].
|
---|---|
Animal Protocol |
Animal/Disease Models: Male C57BL/6 J mice (7 weeks old) in chronic unpredictable mild stress (CUMS) [1]
Doses: 5 and 10 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day, continuous 2-week Experimental Results: diminished immobility in C57BL/6 J mice. The expression of BDNF, pTrkB and pCREB was increased in the hippocampus. Animal/Disease Models: Male C57BL/6 J mice, forced swimming test (FST) and tail suspension test (TST) (7 weeks old) [1] Doses: 5 and 10 mg/kg Route of Administration: intraperitoneal (ip) injection; Experimental Results: diminished immobility of C57BL/6 J mice in FST and TST. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (280-300 g) [2] Doses: 2.5 and 5 mg/kg Route of Administration: Oral; Route of Administration: Oral. Experimental Results: Dose-dependent increase in percentage of time spent with arms open. Increased punishment responses in a dose-dependent manner in the Vogel conflict test. |
References |
[1]. Liu L, et, al. Antidepressant-like activity of L-701324 in mice: A behavioral and neurobiological characterization. Behav Brain Res. 2021 Feb 5;399:113038.
[2]. Kotlinska J, et, al. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology (Berl). 1998 Jan;135(2):175-81. [3]. Hutson PH, et, al. L-701,324, a glycine/NMDA receptor antagonist, blocks the increase of cortical dopamine metabolism by stress and DMCM. Eur J Pharmacol. 1997 May 20;326(2-3):127-32. |
Molecular Formula |
C21H14CLNO3
|
---|---|
Molecular Weight |
363.7938
|
CAS # |
142326-59-8
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C1NC2=C(C=CC(Cl)=C2)C(O)=C1C3=CC=CC(OC4=CC=CC=C4)=C3
|
InChi Key |
FLVRDMUHUXVRET-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C21H14ClNO3/c22-14-9-10-17-18(12-14)23-21(25)19(20(17)24)13-5-4-8-16(11-13)26-15-6-2-1-3-7-15/h1-12H,(H2,23,24,25)
|
Chemical Name |
7-chloro-4-hydroxy-3-(3-phenoxyphenyl)quinolin-2(1H)-one
|
Synonyms |
L701324; L701324; L 701324; L 701324; L-701324; L-701324.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 34 mg/mL (~93.46 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7488 mL | 13.7442 mL | 27.4884 mL | |
5 mM | 0.5498 mL | 2.7488 mL | 5.4977 mL | |
10 mM | 0.2749 mL | 1.3744 mL | 2.7488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.